Clinical Trials

Inclusion Criteria:

- Patients of age ≥18 years who undergo isolated CABG for coronary artery disease

- POAF that persists for >60 minutes or is recurrent (more than one episode) within 7
days after the index CABG surgery

Exclusion Criteria:

- Clinical history of either permanent, persistent or paroxysmal atrial fibrillation

- Any pre-existing clinical indication for long-term OAC

- Any absolute contraindication to OAC

- Planned use of post-operative dual antiplatelet therapy (DAPT)

a. This includes, but is not limited to, patients with recent PCI with drug-eluting or
bare-metal stent.

- Cardiogenic shock

- Major perioperative complication* occurring between CABG and randomization

a. including, but not limited to, stroke, TIA, MI, major bleeding (BARC type 4
bleeding), severe sepsis, renal failure requiring dialysis, or need for reoperation
due to bleeding (e.g. pericardial tamponade).

- Concomitant left atrial appendage closure during CABG

- Concomitant valve surgery during CABG or prior valve surgery (including aortic,
mitral, tricuspid or pulmonary)

- Concomitant mitral valve annuloplasty during CABG

- Concomitant carotid artery endarterectomy during CABG

- Concomitant aortic root replacement during CABG

- Concomitant surgery for AF during CABG

- Liver cirrhosis or Child-Pugh Class C chronic liver disease

- Pharmacologic therapy with an investigational drug or device within 30-days prior to
randomization or plan to enroll patient in an investigational drug or device trial
during participation in this trial

- Pregnancy at the time of randomization

- Unable or unwilling to provide inform consent

- Unable or unwilling to comply with the study treatment and follow-up

- Existence of underlying disease that limits life expectancy to less than one year

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 1/25/24. Questions regarding updates should be directed to the study team contact.